2026 Q4 - tulosraportti
UUTTA
Tänään
‧1 t 1 min
5,00 DKK/osake
Viimeisin osinko
4,77%Tuotto/v
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 10 | ||
| 36 | ||
| 10 | ||
| 15 | ||
| 40 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2027 Q1 - tulosraportti 11.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q4 - tulosraportti 3.11. | ||
2026 Q3 - tulosraportti 18.8. | ||
2026 Q2 - tulosraportti 12.5. | ||
2026 Q1 - tulosraportti 6.2. | ||
Vuosittainen yhtiökokous 2025 4.12.2025 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
·3 t sittenColoplast shows that a quality company can become a poor stock investment if capital allocation deteriorates and the expectations in the share price are high. Organic growth had fallen from a long-term average of approximately 8 % to 6 %, while the company had made significant errors in connection with acquisitions. 1. Return on capital has become significantly lower In 2020/21, Coloplast had an EBIT margin before special items of 33 % and a return on invested capital after tax, ROIC, of 45 %. That was a very strong combination. In 2025/26, the figures were 26 % and 15 %, respectively. The explanation is partly the acquisitions: When you pay a high price, the invested capital grows immediately. Earnings must then keep pace to maintain the return on capital. 2. Coloplast bought growth expensively Atos Medical was acquired in 2022 and financed with debt. Around three-quarters of the purchase price was booked as goodwill. Kerecis was acquired in 2023 for approximately DKK 8.2 billion for the shares, financed through a share issue. The original Kerecis plan was based on approximately 30 % annual revenue growth over three years and an EBIT margin of around 20 % in 2025/26. Those are ambitious assumptions. For existing shareholders, the acquisition must create sufficient extra earnings to also offset the new shares. 3. Kerecis was hit by a risk that changed the investment case Changed US Medicare reimbursement rules for skin substitutes disrupted sales. In the second quarter of 2025/26, Kerecis delivered 0 % organic growth and 0 % EBIT margin before acquisition-related amortization. Coloplast simultaneously wrote down goodwill by DKK 3 billion. The write-down does not cost cash on the day of the write-down. But it shows that the expected future cash flows behind the purchase price have been reduced. It is therefore a capital allocation error. Atos must be assessed separately: The fact that the company was bought expensively does not mean that its operations have failed. Voice & Respiratory Care grew, for example, 8 % organically in 2025/26. 4. FCF is still strong – but does not tell the whole story Coloplast's FCF margin excluding acquisitions and divestments rose to 22 % in 2025/26. Operations thus continue to produce substantial cash flows. But herein lies an important trap: A company can produce great ongoing FCF and then spend the money on acquisitions with insufficient returns. Therefore, one must assess both cash generation and the use of the money. 5. Debt limits operational freedom By September 2026, net debt was approximately DKK 21 billion, corresponding to 2.4 times EBITDA. The year's FCF was approximately DKK 6.3 billion, while paid dividends were approximately DKK 5.2 billion. This leaves less room for rapid debt reduction. 6. The stock can fall more than the earnings themselves The market has reduced both the expectations for future growth and the price it is willing to pay for the earnings. The above is among others from Terry Smith - Fundsmith
- ·4 t sittenColoplast continues to grow, but earns less on sales. The financial report disappoints on operating profit, Kerecis has problems, and growth targets towards 2030 are lowered.
·6 t sittenMorgan Stanley, cutting the price target for the stock to 418 kr. from 454 kr. Then the price will probably drop to 350 to 375.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordea Bank Abp | 9 804 | 9 804 | 0 | 9 804 |
| Danske Bank A/S | 10 000 | 10 000 | 0 | 10 000 |
| Anonyymi | 371 569 | 371 569 | 0 | 0 |
| Skandinaviska Enskilda Banken AB | 7 411 | 7 411 | 0 | 7 411 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordea Bank Abp | 9 804 | 9 804 | 0 | 9 804 |
| Danske Bank A/S | 10 000 | 10 000 | 0 | 10 000 |
| Anonyymi | 371 569 | 371 569 | 0 | 0 |
| Skandinaviska Enskilda Banken AB | 7 411 | 7 411 | 0 | 7 411 |
2026 Q4 - tulosraportti
UUTTA
Tänään
‧1 t 1 min
5,00 DKK/osake
Viimeisin osinko
4,77%Tuotto/v
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·3 t sittenColoplast shows that a quality company can become a poor stock investment if capital allocation deteriorates and the expectations in the share price are high. Organic growth had fallen from a long-term average of approximately 8 % to 6 %, while the company had made significant errors in connection with acquisitions. 1. Return on capital has become significantly lower In 2020/21, Coloplast had an EBIT margin before special items of 33 % and a return on invested capital after tax, ROIC, of 45 %. That was a very strong combination. In 2025/26, the figures were 26 % and 15 %, respectively. The explanation is partly the acquisitions: When you pay a high price, the invested capital grows immediately. Earnings must then keep pace to maintain the return on capital. 2. Coloplast bought growth expensively Atos Medical was acquired in 2022 and financed with debt. Around three-quarters of the purchase price was booked as goodwill. Kerecis was acquired in 2023 for approximately DKK 8.2 billion for the shares, financed through a share issue. The original Kerecis plan was based on approximately 30 % annual revenue growth over three years and an EBIT margin of around 20 % in 2025/26. Those are ambitious assumptions. For existing shareholders, the acquisition must create sufficient extra earnings to also offset the new shares. 3. Kerecis was hit by a risk that changed the investment case Changed US Medicare reimbursement rules for skin substitutes disrupted sales. In the second quarter of 2025/26, Kerecis delivered 0 % organic growth and 0 % EBIT margin before acquisition-related amortization. Coloplast simultaneously wrote down goodwill by DKK 3 billion. The write-down does not cost cash on the day of the write-down. But it shows that the expected future cash flows behind the purchase price have been reduced. It is therefore a capital allocation error. Atos must be assessed separately: The fact that the company was bought expensively does not mean that its operations have failed. Voice & Respiratory Care grew, for example, 8 % organically in 2025/26. 4. FCF is still strong – but does not tell the whole story Coloplast's FCF margin excluding acquisitions and divestments rose to 22 % in 2025/26. Operations thus continue to produce substantial cash flows. But herein lies an important trap: A company can produce great ongoing FCF and then spend the money on acquisitions with insufficient returns. Therefore, one must assess both cash generation and the use of the money. 5. Debt limits operational freedom By September 2026, net debt was approximately DKK 21 billion, corresponding to 2.4 times EBITDA. The year's FCF was approximately DKK 6.3 billion, while paid dividends were approximately DKK 5.2 billion. This leaves less room for rapid debt reduction. 6. The stock can fall more than the earnings themselves The market has reduced both the expectations for future growth and the price it is willing to pay for the earnings. The above is among others from Terry Smith - Fundsmith
- ·4 t sittenColoplast continues to grow, but earns less on sales. The financial report disappoints on operating profit, Kerecis has problems, and growth targets towards 2030 are lowered.
- ·6 t sittenMorgan Stanley, cutting the price target for the stock to 418 kr. from 454 kr. Then the price will probably drop to 350 to 375.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 10 | ||
| 36 | ||
| 10 | ||
| 15 | ||
| 40 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2027 Q1 - tulosraportti 11.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q4 - tulosraportti 3.11. | ||
2026 Q3 - tulosraportti 18.8. | ||
2026 Q2 - tulosraportti 12.5. | ||
2026 Q1 - tulosraportti 6.2. | ||
Vuosittainen yhtiökokous 2025 4.12.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordea Bank Abp | 9 804 | 9 804 | 0 | 9 804 |
| Danske Bank A/S | 10 000 | 10 000 | 0 | 10 000 |
| Anonyymi | 371 569 | 371 569 | 0 | 0 |
| Skandinaviska Enskilda Banken AB | 7 411 | 7 411 | 0 | 7 411 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordea Bank Abp | 9 804 | 9 804 | 0 | 9 804 |
| Danske Bank A/S | 10 000 | 10 000 | 0 | 10 000 |
| Anonyymi | 371 569 | 371 569 | 0 | 0 |
| Skandinaviska Enskilda Banken AB | 7 411 | 7 411 | 0 | 7 411 |
2026 Q4 - tulosraportti
UUTTA
Tänään
‧1 t 1 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2027 Q1 - tulosraportti 11.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q4 - tulosraportti 3.11. | ||
2026 Q3 - tulosraportti 18.8. | ||
2026 Q2 - tulosraportti 12.5. | ||
2026 Q1 - tulosraportti 6.2. | ||
Vuosittainen yhtiökokous 2025 4.12.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
5,00 DKK/osake
Viimeisin osinko
4,77%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·3 t sittenColoplast shows that a quality company can become a poor stock investment if capital allocation deteriorates and the expectations in the share price are high. Organic growth had fallen from a long-term average of approximately 8 % to 6 %, while the company had made significant errors in connection with acquisitions. 1. Return on capital has become significantly lower In 2020/21, Coloplast had an EBIT margin before special items of 33 % and a return on invested capital after tax, ROIC, of 45 %. That was a very strong combination. In 2025/26, the figures were 26 % and 15 %, respectively. The explanation is partly the acquisitions: When you pay a high price, the invested capital grows immediately. Earnings must then keep pace to maintain the return on capital. 2. Coloplast bought growth expensively Atos Medical was acquired in 2022 and financed with debt. Around three-quarters of the purchase price was booked as goodwill. Kerecis was acquired in 2023 for approximately DKK 8.2 billion for the shares, financed through a share issue. The original Kerecis plan was based on approximately 30 % annual revenue growth over three years and an EBIT margin of around 20 % in 2025/26. Those are ambitious assumptions. For existing shareholders, the acquisition must create sufficient extra earnings to also offset the new shares. 3. Kerecis was hit by a risk that changed the investment case Changed US Medicare reimbursement rules for skin substitutes disrupted sales. In the second quarter of 2025/26, Kerecis delivered 0 % organic growth and 0 % EBIT margin before acquisition-related amortization. Coloplast simultaneously wrote down goodwill by DKK 3 billion. The write-down does not cost cash on the day of the write-down. But it shows that the expected future cash flows behind the purchase price have been reduced. It is therefore a capital allocation error. Atos must be assessed separately: The fact that the company was bought expensively does not mean that its operations have failed. Voice & Respiratory Care grew, for example, 8 % organically in 2025/26. 4. FCF is still strong – but does not tell the whole story Coloplast's FCF margin excluding acquisitions and divestments rose to 22 % in 2025/26. Operations thus continue to produce substantial cash flows. But herein lies an important trap: A company can produce great ongoing FCF and then spend the money on acquisitions with insufficient returns. Therefore, one must assess both cash generation and the use of the money. 5. Debt limits operational freedom By September 2026, net debt was approximately DKK 21 billion, corresponding to 2.4 times EBITDA. The year's FCF was approximately DKK 6.3 billion, while paid dividends were approximately DKK 5.2 billion. This leaves less room for rapid debt reduction. 6. The stock can fall more than the earnings themselves The market has reduced both the expectations for future growth and the price it is willing to pay for the earnings. The above is among others from Terry Smith - Fundsmith
- ·4 t sittenColoplast continues to grow, but earns less on sales. The financial report disappoints on operating profit, Kerecis has problems, and growth targets towards 2030 are lowered.
- ·6 t sittenMorgan Stanley, cutting the price target for the stock to 418 kr. from 454 kr. Then the price will probably drop to 350 to 375.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 10 | ||
| 36 | ||
| 10 | ||
| 15 | ||
| 40 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Asiakkaat katsoivat myös
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordea Bank Abp | 9 804 | 9 804 | 0 | 9 804 |
| Danske Bank A/S | 10 000 | 10 000 | 0 | 10 000 |
| Anonyymi | 371 569 | 371 569 | 0 | 0 |
| Skandinaviska Enskilda Banken AB | 7 411 | 7 411 | 0 | 7 411 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordea Bank Abp | 9 804 | 9 804 | 0 | 9 804 |
| Danske Bank A/S | 10 000 | 10 000 | 0 | 10 000 |
| Anonyymi | 371 569 | 371 569 | 0 | 0 |
| Skandinaviska Enskilda Banken AB | 7 411 | 7 411 | 0 | 7 411 |